# Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

> **NCT03724942** · PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 164 (actual)

## Conditions studied

- Agitation Associated With Dementia of the Alzheimer's Type

## Interventions

- **DRUG:** Brexpiprazole

## Key facts

- **NCT ID:** NCT03724942
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-09
- **Primary completion:** 2021-12-02
- **Final completion:** 2022-01-05
- **Target enrollment:** 164 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03724942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03724942, "Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03724942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*